Evidence analysisNovember 5, 2026Evidence
PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – December 2026, Online, from 9 December 2026, 09:30 (CET) to 9 December 2026, 10:30 (CET)

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
The European Medicines Agency (EMA) hosts a public event titled “PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API)” scheduled for 9 December 2026. This event provides an opportunity for stakeholders, particularly from the pharmaceutical industry and National Competent Authorities (NCAs), to engage with the EMA’s Product Management Service (PMS) team on technical aspects related to accessing and managing medicinal product data.
The Product User Interface (PUI) and Application Programming Interface (API) are digital tools provided by the EMA that facilitate data access for both centrally authorised products (CAPs) and non-centrally authorised products (non-CAPs). Non-CAPs include medicines authorised via mutual recognition procedure (MRP), decentralised procedure (DCP), and national procedure (NAP).
Since 31 January 2025, the PUI is available in edit mode exclusively for industry users managing data on non-CAP human medicines. NCAs can access the PUI only in read-only mode. The PMS API, which provides read-only data access, is available to both NCAs and industry users.
What the source claims
- The EMA will conduct an online Q&A session to address questions about the PMS digital tools (PUI and API) related to product data management.
- The PUI edit mode is targeted at industry users for managing non-CAP human medicines data, designed to streamline data entry and maintenance functions.
- The read-only access for NCAs aims to support regulatory oversight and harmonisation by enabling consistent data consultation across member states.
- The PMS API extends data availability in a machine-readable format, facilitating integration into regulatory and industry IT systems.
- This framework supports transparency and efficient management of medicinal product information across different authorisation routes in the EU.
What may be missing from the usual framing
The announcement does not provide details on user experience challenges, such as technical difficulties or training needs, which are often significant when introducing new digital tools in regulated environments. Moreover, there is no discussion on data security or privacy considerations relevant to these interfaces—key concerns when handling sensitive medicinal product information.
The broader impact on regulatory workload and decision-making processes is not explicitly addressed. For example, whether the PUI and API will reduce administrative burden or if further manual validation remains necessary is unclear.
Furthermore, the event focuses on human medicines, with no mention of veterinary products or other medicinal categories, which may also be governed by related EMA systems.
Competing evidence or uncertainty
The EMA source provides official information without presenting alternative viewpoints or independent assessments. There is insufficient evidence to evaluate the effectiveness or adoption rate of these digital services post-deployment.
No data is available from this source on user feedback, technical performance, or comparative benefits relative to previous systems.
Without user case studies or audits, it remains uncertain if the PUI/API meet the diverse needs of all stakeholders or encounter operational barriers.
Why it matters
Robust digital tools for managing medicinal product data are essential for regulatory transparency, public safety, and timely access to accurate medicine information. The EMA’s development of the PUI and API aims to modernise data handling, enhance cross-national regulatory harmonisation, and facilitate industry compliance.
By enabling streamlined data exchange, these tools could accelerate decision-making, improve pharmacovigilance, and support innovation in medicines regulation. However, if these interfaces lack usability or fail to address implementation challenges, they risk adding complexity or reducing data reliability.
Understanding these developments helps stakeholders—including patients, healthcare professionals, regulators, and industry—monitor how medicine information governance evolves in the EU regulatory framework.
What to verify next
- Obtain user feedback and independent evaluations on the functionality, usability, and impact of the PUI and API since their rollout.
- Review any EMA reports or updates addressing security, data integrity, or regulatory outcomes related to these digital tools.
- Investigate if broader stakeholder groups beyond industry and NCAs have access or engagement with the system, including public transparency portals.
- Examine any integration of these tools with other EU health data systems or international regulatory databases.
- Assess training programs or support mechanisms accompanying the PUI and API implementation to understand user readiness and ongoing challenges.
Readers are encouraged to consult the original EMA notice for the full context of the PMS Q&A Clinic event and associated resources.
Source & verification
Primary source: What's new · November 5, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Burkina Faso Targets Critics in Exile
Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…

Human Rights Watch Mourns Death of Activist Nabeel Rajab
Human Rights Evidence Dossier: The Life and Legacy of Nabeel Rajab What is established Nabeel Rajab, a Bahraini human rights activist well-known for his…

Two more journalists murdered in Latin America, prompting press freedom concerns
Two More Journalists Murdered in Latin America: Press Freedom Under Threat In November 2026, Latin America witnessed a violent escalation against the press with…